ADC Therapeutics (ADCT) Net Income towards Common Stockholders (2023 - 2026)
ADC Therapeutics' (ADCT) quarterly Net Income towards Common Stockholders came in at -$33.0 million in Q1 2026, up 14.6% year-on-year from -$28.8 million in Q1 2025, and up 19.52% quarter-over-quarter from -$41.0 million in Q3 2025.
ADC Therapeutics (ADCT) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Net Income towards Common Stockholders across 4 years of filings, most recently posting -$33.0 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | -32.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.97 Mn |
| Sep 30, 2025 | -40.97 Mn |
| Jun 30, 2025 | -56.65 Mn |
| Mar 31, 2025 | -38.60 Mn |
| Sep 30, 2024 | -43.71 Mn |
| Jun 30, 2024 | -35.95 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Sep 30, 2023 | -45.32 Mn |
| Jun 30, 2023 | -48.15 Mn |